Skip to main content
NXGLW logo

NEXGEL, Inc. (NXGLW) Stock Price & Analysis

NEXGEL, Inc. (NXGLW) — price $0.0098 (+13.95%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.0098 +$0.0012 (+13.95%)

NEXGEL, Inc. · NXGLW

NEXGEL, Inc. specializes in manufacturing and selling hydrogels for various applications, including wound care and cosmetics. The company operates through its Nexgel and CG labs segments, focusing on over-the-counter remedies and developing advanced medical products.

Price as of Nov 19, 2026

Key Statistics

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ISRG · Intuitive Surgical, Inc. · 94 /100
  • BDX · Becton, Dickinson and Company · 68 /100
  • MDLN · Medline Inc. Class A Common Stock · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0098
Change on the day+13.95%
52-week range$0.005 – $0.314
Shares traded on the day7.5K

Price & events

1 · What is it?

What is NEXGEL (NXGLW), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. NEXGEL, Inc. (NXGLW) is the company analyzed here. It employs 19 people and is led by Brian J. Kieser. In Q2 FY2026 it reported revenue of $4M and net income of -$4M.

2 · Latest results

What do the latest results show for NEXGEL (NXGLW)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $4M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$4M-$4M-$8.07 (diluted)
Q1 FY2026$3M-$927,000-$2.26 (diluted)
Q4 FY2025$3M-$970,000-$2.41 (diluted)
Q3 FY2025$3M-$653,000-$1.64 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for NEXGEL (NXGLW)?

Short answer · as of

The distress and quality screens read Altman Z -1.83 · Piotroski F 2. Trailing ratios: ROA -23.4% · current ratio 0.43.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -1.83 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held NXGLW in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported NXGLW in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Common Questions About NXGLW

These answers are editorial: 1 of these 1 answer is drawn from the NXGLW research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.

What does NEXGEL, Inc. do?

NEXGEL, Inc. specializes in the development, manufacturing, and sale of high water content hydrogels. These hydrogels are used in a variety of applications, including wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.